Fusion Round

First Patient Dosed in Fusion Phase I trial.

Boston, Massachusetts & Hamilton, Ontario.  February 19, 2019.  Seroba portfolio company, Fusion Pharmaceuticals, a biopharmaceutical company focused on radiotherapeutics (targeted alpha therapeutics) has announced the first patient was dosed in a Phase 1, first-in-human clinical trial of lead product candidate [225Ac]-FPI-1434 in patients with advanced solid tumors. “The entire Fusion team takes tremendous pride in […]

First Patient Dosed in Fusion Phase I trial. Read More »